J Cancer 2013; 4(4):323-329. doi:10.7150/jca.6226 This issue

Research Paper

Plasma Cell-Free DNA in Paediatric Lymphomas

Lara Mussolin1,2 ✉, Roberta Burnelli3, Marta Pillon2, Elisa Carraro2, Piero Farruggia4, Alessandra Todesco2, Maurizio Mascarin5, Angelo Rosolen2

1. Istituto di Ricerca Pediatrico Fondazione Città della Speranza, Padova Italy;
2. Clinica di Oncoematologia Pediatrica, Azienda Ospedaliera-Università di Padova, Padova, Italy;
3. Onco-hematology Unit, Az Ospedaliero-Universitaria di Ferrara S.Anna;
4. Pediatric Hematology and Oncology Unit, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Palermo, Italy;
5. Department of Radiotherapy, Centro di Riferimento Oncologico, Aviano, Pordenone, Italy; on behalf of the Linfoma non-Hodgkin and Linfoma di Hodgkin Working Groups AIEOP (Associazione Italiana Emato-Oncologia Pediatrica).

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Mussolin L, Burnelli R, Pillon M, Carraro E, Farruggia P, Todesco A, Mascarin M, Rosolen A. Plasma Cell-Free DNA in Paediatric Lymphomas. J Cancer 2013; 4(4):323-329. doi:10.7150/jca.6226. Available from https://www.jcancer.org/v04p0323.htm

File import instruction


Background: Extracellular circulating DNA (cfDNA) can be found in small amounts in plasma of healthy individuals. Increased levels of cfDNA have been reported in patients with cancer of breast, cervix, colon, liver and it was shown that cfDNA can originate from both tumour and non-tumour cells.

Objectives: Levels of cfDNA of a large series of children with lymphoma were evaluated and analyzed in relation with clinical characteristics.

Methods: plasma cfDNA levels obtained at diagnosis in 201 paediatric lymphoma patients [43 Hodgkin lymphomas (HL), 45 anaplastic large cell lymphomas (ALCL), 88 Burkitt lymphomas (BL), 17 lymphoblastic (LBL), 8 diffuse large B cell lymphoma (DLBCL)] and 15 healthy individuals were determined using a quantitative PCR assay for POLR2 gene and, in addition, for NPM-ALK fusion gene in ALCL patients. Wilcoxon rank sum test was used to compare plasma levels among different patient subgroups and controls and to analyze relationship between levels of cfDNA and clinical characteristics.

Results: Levels of cfDNA in lymphoma patients were significantly higher compared with controls (p<0.0001). CfDNA was associated with median age (p=0.01) in HL, and with stage in ALCL (p=0.01). In HL patients high cfDNA levels were correlated with poor prognosis (p=0.03). In ALCL we found that most of the cfDNA (77%) was non-tumor DNA.

Conclusion: level of plasma cfDNA might constitute an important non-invasive tool at diagnosis in lymphoma patients' management; in particular in patients with HL, cfDNA seems to be a promising prognostic biomarker.

Keywords: lymphoma, childhood, cfDNA, prognosis, Hodgkin.